Amyloid beta aggregates are seen as a hallmark sign of Alzheimer’s disease, and they are the suspected link to neuronal death. It is viewed that the uptake of amyloid beta peptides into the neuron via vesicles causes formation of aggregates which leads to neurotoxicity, and ultimately cell death. Aggregates are formed when amyloid beta peptides fold on to each other; this study argued that this misfolding of the protein results in aggregation before entrance into the cell.
World Alzheimer’s Day, Wednesday September 21st marked the launch of Canada’s largest dementia focused study. This $8.4 million study is being funded by a $31.5 million grant awarded by the federal government through the Canadian Institutes of Health Research, awarded for the development of the Canadian Consortium on Neurodegenerative Aging. This study is being led by Dr. Howard Chertkow at the Jewish General Hospital, but will bring together approximately 350 researchers across Canada.
Ontario has launched an online survey and in person consultations to help develop a new dementia strategy. The goal of this strategy is to improve access to care and boost supports for caregivers. After releasing a discussion paper (Developing Ontario’s Dementia Strategy) based on the feedback of health care providers, persons with dementia and their care partners; Ontario is looking for public input on key issues.
This work sought out to answer the question, why do some amyloid beta (Aβ) peptides aggregate whereas some do not. In this study they determined the conditions in which aggregation of Aβ peptides is most probable to occur.
Taking a look into the available treatments for Alzheimer’s disease the FDA states that there are limited options. The FDA has only approved 5 drugs for the treatment of Alzheimer’s, the most recent drug approved was in 2003.